Evaluation of prostate-specific antigen and total serum acid phosphatase in prostatic carcinoma

Jaswinder Singh; Dinesh Kumar Pasi; Manju Bala; Ashwani Kumar; Amarjit Singh; Ruchi Jakhar; Akanksha Sharma; Anshu Saini

doi:10.5455/njppp.2023.13.03140202304042023

2023, Vol: 13, Issue: 5

13/5Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Natl J Physiol Pharm Pharmacol. 2023; 13(5): 1065-1071

doi: 10.5455/njppp.2023.13.03140202304042023

Evaluation of prostate-specific antigen and total serum acid phosphatase in prostatic carcinoma

Jaswinder Singh, Dinesh Kumar Pasi, Manju Bala, Ashwani Kumar, Amarjit Singh, Ruchi Jakhar, Akanksha Sharma, Anshu Saini.

Abstract
Background: The importance of prostatic carcinoma and its detection has increased manifold over the last few decades. Total serum acid phosphatase (ACP) was the world’s first emerged clinically useful tumor marker in the 1940s and 1950s in patients with prostatic diseases. With the introduction of the prostatic specific antigen (PSA) test in the 1980s, which performed significantly better in screening and treatment programs bringing disfavor to the advent of ACP.

Aims and Objectives: To determine serum PSA and total serum ACP in patients with prostatic cancer and benign prostatic diseases, followed by evaluation of these tumor markers.

Materials and Methods: This study was conducted on 30 patients with histologically proven cases of prostatic carcinoma and compared against 30 patients as control with benign prostatic pathology, residing in Punjab who were admitted and treated with symptoms complex of prostatism or retention urine or other urinary complaints as the primary symptoms. PSA and ACP in serum were determined using ELISA test kit and King and Kind method, respectively.

Results: The mean level of serum PSA was 81.19 ± 49.02 for cancer prostate and 4.975 for benign prostatic diseases, while the mean level of serum ACP was 5.22 ± 1.70 and 2.52 ± 2.27, respectively, for the cancer prostate and benign prostatic diseases showing statistically difference between study and control groups was highly significant as P < 0.0001.

Conclusion: Statistical analysis and results of the present study indicated that although serum ACP has better specificity to PSA, yet later is a very sensitive tumor marker in prostate diseases for screening, diagnosis, and post-treatment follow-up.

Key words: Serum Prostatic-Specific Antigen; Total Serum Acid Phosphatase; Prostate Carcinoma; Benign Prostatic Diseases and Punjab State

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Jaswinder Singh Articles by Dinesh Kumar Pasi Articles by Manju Bala Articles by Ashwani Kumar Articles by Amarjit Singh Articles by Ruchi Jakhar Articles by Akanksha Sharma Articles by Anshu Saini
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Singh J, Pasi DK, Bala M, Kumar A, Singh A, Jakhar R, Sharma A, Saini A. Evaluation of prostate-specific antigen and total serum acid phosphatase in prostatic carcinoma. Natl J Physiol Pharm Pharmacol. 2023; 13(5): 1065-1071. doi:10.5455/njppp.2023.13.03140202304042023

Web Style

Singh J, Pasi DK, Bala M, Kumar A, Singh A, Jakhar R, Sharma A, Saini A. Evaluation of prostate-specific antigen and total serum acid phosphatase in prostatic carcinoma. https://www.njppp.com/?mno=146824 [Access: May 01, 2023]. doi:10.5455/njppp.2023.13.03140202304042023

AMA (American Medical Association) Style

Singh J, Pasi DK, Bala M, Kumar A, Singh A, Jakhar R, Sharma A, Saini A. Evaluation of prostate-specific antigen and total serum acid phosphatase in prostatic carcinoma. Natl J Physiol Pharm Pharmacol. 2023; 13(5): 1065-1071. doi:10.5455/njppp.2023.13.03140202304042023

Vancouver/ICMJE Style

Singh J, Pasi DK, Bala M, Kumar A, Singh A, Jakhar R, Sharma A, Saini A. Evaluation of prostate-specific antigen and total serum acid phosphatase in prostatic carcinoma. Natl J Physiol Pharm Pharmacol. (2023), [cited May 01, 2023]; 13(5): 1065-1071. doi:10.5455/njppp.2023.13.03140202304042023

Harvard Style

Singh, J., Pasi, . D. K., Bala, . M., Kumar, . A., Singh, . A., Jakhar, . R., Sharma, . A. & Saini, . A. (2023) Evaluation of prostate-specific antigen and total serum acid phosphatase in prostatic carcinoma. Natl J Physiol Pharm Pharmacol, 13 (5), 1065-1071. doi:10.5455/njppp.2023.13.03140202304042023

Turabian Style

Singh, Jaswinder, Dinesh Kumar Pasi, Manju Bala, Ashwani Kumar, Amarjit Singh, Ruchi Jakhar, Akanksha Sharma, and Anshu Saini. 2023. Evaluation of prostate-specific antigen and total serum acid phosphatase in prostatic carcinoma. National Journal of Physiology, Pharmacy and Pharmacology, 13 (5), 1065-1071. doi:10.5455/njppp.2023.13.03140202304042023

Chicago Style

Singh, Jaswinder, Dinesh Kumar Pasi, Manju Bala, Ashwani Kumar, Amarjit Singh, Ruchi Jakhar, Akanksha Sharma, and Anshu Saini. "Evaluation of prostate-specific antigen and total serum acid phosphatase in prostatic carcinoma." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 1065-1071. doi:10.5455/njppp.2023.13.03140202304042023

MLA (The Modern Language Association) Style

Singh, Jaswinder, Dinesh Kumar Pasi, Manju Bala, Ashwani Kumar, Amarjit Singh, Ruchi Jakhar, Akanksha Sharma, and Anshu Saini. "Evaluation of prostate-specific antigen and total serum acid phosphatase in prostatic carcinoma." National Journal of Physiology, Pharmacy and Pharmacology 13.5 (2023), 1065-1071. Print. doi:10.5455/njppp.2023.13.03140202304042023

APA (American Psychological Association) Style

Singh, J., Pasi, . D. K., Bala, . M., Kumar, . A., Singh, . A., Jakhar, . R., Sharma, . A. & Saini, . A. (2023) Evaluation of prostate-specific antigen and total serum acid phosphatase in prostatic carcinoma. National Journal of Physiology, Pharmacy and Pharmacology, 13 (5), 1065-1071. doi:10.5455/njppp.2023.13.03140202304042023

Author Login Reviewer Login About Publisher Editorial Policies Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information



Copyright © 2023 National Journal of Physiology, Pharmacy and Pharmacology All Rights Reserved. Subject to change without notice from or liability to National Journal of Physiology, Pharmacy and Pharmacology. For best results, please use Internet Explorer or Google Chrome	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272

Contact Information

How to cite this article